Here to listen, inform & support - For general enquiries call 01223-870008
Health Professional | FAQ | Scotland
Recently Diagnosed Find Support
Donate
DR and PAtient homepage slider

About Kidney Cancer

Welcome to Kidney Cancer UK. Here you will find information to help you if you are newly
diagnosed, undergoing or following treatment on a wide range of subject relating to
including Symptoms, treatments, living with kidney cancer and information videos

LEARN MORE
Kidney cancer counselling

Support & Wellbeing

If you need support and would like to talk to our Counsellor or Careline, are in
need of literature including our Living With Kidney Cancer booklets, would like to view
our wide range of informative exercise, dietary or yoga and more videos, this is the area for you.

LEARN MORE
Kidney Cancer Nurses

Research and Training

Here you will find a programme to help you find a clinical trial to suit you, information relating
to research programmes we are funding ad how you can apply for such fund along
with information on our Peer Review process.

LEARN MORE
Donate to kidney cancer UK

Fundraise & Donate

Every pound you donate and every minute of your time makes a difference to
people with, or those effected by, kidney cancer. Here you will find the many ways to
fundraise, easily donate, set up standing order which helps us to help others.

LEARN MORE

What's New?

Living With Kidney Cancer days

Check the dates for our nine free to attend, Living With Kidney Cancer days 2019.
Read More

Patient Survey Results Autumn 2018

Almost half of kidney cancer patients suffer initial misdiagnosis. Read the results from our Patient survey, Autumn 2018.
Read More

Kidney Cancer Counselling Service

Kidney Cancer UK and Kidney Cancer Scotland provide the UK's first, free, dedicated Kidney Cancer Counselling Service.
Read More

Clinical Trials

Every year, more than half a million people help the NHS improve healthcare and develop life-saving treatments by taking part in clinical trials.
Read More

Latest News

Read All News
  • kiltwalk

    KiltWalk 2019

    15 Mar 2019

    We are delighted to be participating in the Kiltwalk fundraising events in Scotland throughout 2019

    Glasgow Sunday 28 April

    Aberdeen Sunday 2nd June

    Dundee Sunday 18th August

    Edinburgh Sunday 15th September

    We are delighted to be participating in the Kiltwalk fundraising events in Scotland. Charities participating in the events will see their fundraising topped up to an incredible 40%, every penny raised going to our Charity so let’s get involved, get fit, have fun and raise some money!

    Call us on 07769 261777  or email fundraising@kidneycancerscot.org to join us

    Choose from:

    The Mighty Stride (approx. 23 miles),
    The Big Stroll (approx. 14 miles) or the
    Wee Wander (approx. 6 miles).

    There is a walk to suit everyone.

    Before you register contact us as we have a limited amount of pin codes and we will cover your entry costs so please, if you are interested, let us know and we will tell you what to do next.

    Alternatively, you can visit the Kiltwalk here

     

  • Kidney animation slider image

    EMA validates Bavencio for review in advanced RCC

    12 Mar 2019

    The European Medicines Agency (EMA) has validated Merck’s application for Bavencio (avelumab) for the treatment of patients with advanced renal cell carcinoma (RCC).

    The review is for the Type II variation application of the drug in combination with Inlyta (axitinib), and is based on results from the pivotal Phase III JAVELIN Renal 101 trial.

    JAVELIN involves at least 30 clinical programs and more than 9,000 patients evaluated across more than 15 different tumor types. In addition to RCC, these tumor types include breast, gastric/gastro-esophageal junction, and head and neck cancers, Merkel cell carcinoma, non-small cell lung cancer, and urothelial carcinoma.

    The trial results were published in the New England Journal of Medicine on February 16, 2019.

    The US Food and Drug Administration (FDA) has also accepted a supplemental Biologics License Application for the drug combination, for patients with advanced RCC for Priority Review.

    The target date is June 2019, and a supplemental application for the combination in unresectable or metastatic RCC has also been submitted in Japan.

    Author: PharmaTimes.

    To read full article click here.

  • Welder is welding assembly automotive part in car factory

    Welding Linked to Kidney Cancer

    06 Mar 2019

    HSE issues a safety alert for welding fume exposure in kidney and lung cancer

    This is an alert for anyone who is, or knows of anyone, undertaking welding as their job or hobby.

    The Health and Safety Executive has issued a safety alert as a result of new scientific evidence which suggests that exposure to all welding fume, including mild steel welding fume, can cause lung cancer and has shown evidence linking to kidney cancer.

    We have used a copy from Welding World magazine by kind permission to relay this news.

    As part of bulletin number STSU1 – 2019, the HSE has issued a change in HSE enforcement expectations in relation to the control of exposure of welding fume, including that from mild steel welding.

    All those undertaking welding activities should ensure effective engineering controls are provided and correctly used to control fume arising from those welding activities and where engineering controls are not adequate to control all fume exposure, adequate and suitable respiratory protective equipment (RPE) is also required to control risk from the residual fume.

    There is also limited evidence linked to kidney cancer. The alert was issued after new scientific evidence from the International Agency for Research on Cancer suggested that exposure to mild steel welding fume can cause lung cancer and

    possibly kidney cancer in humans. The Workplace Health Expert Committee has endorsed the reclassification of mild steel welding fume as a human carcinogen.

    As a result of this with immediate effect, there is a strengthening of HSE’s enforcement expectation for all welding fume, including mild steel welding; because general ventilation does not achieve the necessary control.

    In order to control the cancer risk those involved in the process will require suitable engineering controls for all welding activities indoors e.g. Local Exhaust Ventilation (LEV). Extraction will also control exposure to manganese, which is present in mild steel welding fume, which can cause neurological effects similar to Parkinson’s disease.

    Welder is welding assembly automotive part in car factory

    Where LEV alone does not adequately control exposure, it should be supplemented by adequate and suitable respiratory protective equipment (RPE) to protect against the residual fume.

    Appropriate RPE should be provided for welding outdoors. Those involved should also ensure welders are suitably instructed and trained in the use of these controls.

    Regardless of duration, the HSE will no longer accept any welding undertaken without any suitable exposure control measures in place, as there is no known level of safe exposure.

    Risk assessments should reflect the change in the expected control measures.

    It is now required that those involved in the process should:

    1. Make sure exposure to any welding fume released is adequately controlled using engineering controls (typically LEV).
    2. Make sure suitable controls are provided for all welding activities, irrelevant of duration. This includes welding outdoors.
    3. Where engineering controls alone cannot control exposure, then adequate and suitable RPE should be provided to control risk from any residual fume.
    4. Make sure all engineering controls are correctly used, suitably maintained and are subject to thorough examination and test where required.
    5. Make sure any RPE is subject to an RPE programme. An RPE programme encapsulates all the elements of RPE use needed to ensure that the RPE undertaken is effective in protecting the wearer.

    Author: HSE-( Health and Safety Executive). Bulletin No STSU1-2019 – issue date February 2019

     

  • take our survey

    Survey -Developing a tool to personalise treatment in small kidney tumours

    20 Feb 2019

    If you are taking this survey on a mobile device, please CLICK HERE.

    Create your own user feedback survey

  • European Commission approves nivolumab ipilimumab combo

    16 Jan 2019

    The European Commission has approved nivolumab in combination with low-dose ipilimumab for first-line treatment of patients with intermediate and poor risk advanced renal cell carcinoma (RCC).

    The company says the approval marks the first of an immuno-oncology (I-O) combination therapy for patients with this type of cancer in the European Union.

    Clearance is based on results from the Phase III CheckMate-214 clinical trial, which was stopped early following an interim analysis showing that the Opdivo (nivolumab) and Yervoy (ipilimumab) combination showed a significant increase in overall survival, with a 37% decreased risk of death compared to currently used, Sutent (sunitinib).

    The combination also demonstrated a higher objective response rate of 41.6%, versus 26.5% for Sutent.

    “Currently, less than 50% of patients with metastatic renal cell carcinoma survive beyond two years, and there is almost no complete remission observed, which underscores the need for new treatments for this disease,” said Bernard Escudier, ex-chairman of the Genitourinary Oncology Committee, Institut Gustave Roussy.

    He continued, “Today’s approval offers patients in the European Union a first-line treatment option that has demonstrated a complete response rate of almost 10% and a significant improvement in overall survival with fewer Grade 3 and 4 adverse reactions compared to sunitinib.”

     

    READ THE FULL STORY ON PharmaTimes HERE

  • Seed header

    Kidney Cancer Awareness Week 4-8 February 2019

    07 Jan 2019

    ‘Plant a seed for research’ in Kidney Cancer Awareness Week

    Sunflower

    Sunflower

    We are are pleased to announce that Monday 4th February to Friday 8th February will be our annual Kidney Cancer Awareness Week 2019 (#KCAW2019) across the United Kingdom and culminating with Green Friday on 8th February.

    This year we are calling for the Government to invest in research for a national kidney cancer screening programme as our UK patient survey revealed that 47% of patients are diagnosed at stage 3 or later. This is not acceptable and the Governments own pledge to diagnose 75% of cancers at stage 1 or 2 by 2028 in their recently announced ‘NHS Long Term Plan’ is too far in the future. This is needed within five years.

    Kidney Cancer UK and Kidney Cancer Scotland are currently supporting research into a national kidney cancer screening programme and ask you for your support by joining in our ‘Plant a seed for research’ campaign. For a minimum donation of £5.00 we will send you a pack of seed to plant from which hope and new life will grow through the research we support. The seed will be loose packed and randomly selected from Cornflower, Sunflower, Nasturtium and Corn Marigold. 100% of the profit from your donation will go to research into kidney cancer. You can join in ‘Plant a seed for research’ by clicking HERE.

    Once your seeds start to bloom in the summer you can share pictures of your lovely flowers via our Facebook page.

    Kidney Cancer Awareness Week culminates with Green Friday (8th February) when we ask everyone to wear as much green as possible to show their support for all kidney cancer patients, their families and carers. We want to drive conversations and move kidney cancer in the the general awareness so the public are aware and GP’s, consultants and all medical specialists have kidney cancer high on their radar when patients present to them. On Green Friday we would love for you to share your pictures via our Facebook page.

    Despite being the seventh most common cancer in the UK: the fifth most common in men and the tenth in women, kidney cancer remains relatively unheard of.  Each year, in the UK 12,500 people are diagnosed with kidney cancer and it accounts for three per cent of all new diagnoses. Forty-two per cent of kidney cancer cases are linked to major lifestyle factors; including smoking and obesity.

    corn marigold

    Corn Marigold

    We will continue to highlight findings of our Autumn Kidney Cancer Patient Survey 2018 with the objective of increasing the nation’s awareness and improving conditions for those with kidney cancer.

    It is important to always talk about kidney cancer, the importance of early diagnosis and promote awareness that this is a silent killer; we simply do not know who it will strike next. Be aware of the 10 signs of kidney cancer:

    Cornflower

    Cornflower

    1. Blood in the urine
    2. Persistent low back pain
    3. Pain in the side, between the ribs and hipbone
    4. A lump or mass in the area of the kidneys
    5. Persistent high temperature
    6. Night sweats

    Nasturtium

    Nasturtium

    7. Persistent cough
    8. Tiredness
    9. Weight loss
    10. Loss of appetite

     

    Read our  Kidney Cancer UK Patient Survey here:

     

    As well as the highlighting of the survey, an online social media campaign will run in the weeks leading up to, and on the day with special messaging using the hashtag #KCAW2019 so everyone can instantly join the online conversation.

    JOIN THE CONVERSATION, SPREAD THE WORD!

    With this Kidney Cancer Awareness Week we want everyone to unite in the fight against kidney cancer, start a conversation and keep talking and ask the question; What will you do to ‘Make some noise about kidney cancer’ in Kidney Cancer Awareness Week 2019?

    Use the hashtag across all social media platforms #KCAW2019

    Through this simple act we can make a difference and save lives.

Latest Videos

See all videos

Support Lines

 
 
Top